Tags

Type your tag names separated by a space and hit enter

The impact of routine childhood immunization with higher-valent pneumococcal conjugate vaccines on antimicrobial-resistant pneumococcal diseases and carriage: a systematic literature review.
Expert Rev Vaccines. 2019 10; 18(10):1069-1089.ER

Abstract

Introduction: The introduction of 7-valent pneumococcal conjugate vaccine (PCV7) in childhood immunization programs reduced antimicrobial-resistant pneumococcal infections by vaccine serotypes. However, emerging antimicrobial-resistant non-vaccine serotypes, particularly serotype 19A, attenuated the overall effect. In 2010, higher-valent PCVs became available containing serotypes that are prone to become antimicrobial-resistant, like serotype 7F in PCV10 and PCV13, and serotype 19A in PCV13.Areas covered: This review evaluated literature published between June 1, 2008 and June 1, 2017 reporting on the effect of PCV10 or PCV13 implementation in routine infant immunization schedules on antimicrobial-resistant invasive pneumococcal disease (IPD), otitis media (OM), and nasopharyngeal carriage (NPC) in children and adults.Expert opinion: In countries with relatively high prior pneumococcal antimicrobial resistance (AMR), PCV13 childhood vaccination programs have reduced antimicrobial-resistant IPD, OM, and NPC in children and IPD in adults. The effectiveness of PCV13 against serotype 19A is likely an important contributing factor. Only few studies have documented the impact of PCV10 on AMR. Multiple factors may influence observed decreases in pneumococcal AMR including antimicrobial stewardship, case definition, time since PCV10/13 introduction, and pre-PCV10/13 AMR levels. This review emphasizes the importance of including impact on AMR when evaluating the full public health of pneumococcal vaccination programs.

Authors+Show Affiliations

Clinical Epidemiology, Pfizer Inc, Paris, France.Department of Epidemiology, P95 Epidemiology and Pharmacovigilance, Leuven, Belgium.Vaccines Medical Development & Scientific/Clinical Affairs, Pfizer Inc, Collegeville, PA, USA.Department of Epidemiology, P95 Epidemiology and Pharmacovigilance, Leuven, Belgium.Department of Health Economic & Outcomes Research, Pfizer Inc, New York, NY, USA.Vaccines Medical Development & Scientific/Clinical Affairs, Pfizer Inc, Collegeville, PA, USA.Department of Epidemiology, P95 Epidemiology and Pharmacovigilance, Leuven, Belgium.Vaccines Medical Development & Scientific/Clinical Affairs, Pfizer Inc, Collegeville, PA, USA.Vaccines Medical Development & Scientific/Clinical Affairs, Pfizer Inc, Paris, France.Vaccines Medical Development & Scientific/Clinical Affairs, Pfizer Inc, Collegeville, PA, USA.

Pub Type(s)

Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review

Language

eng

PubMed ID

31585049

Citation

Tin Tin Htar, Myint, et al. "The Impact of Routine Childhood Immunization With Higher-valent Pneumococcal Conjugate Vaccines On Antimicrobial-resistant Pneumococcal Diseases and Carriage: a Systematic Literature Review." Expert Review of Vaccines, vol. 18, no. 10, 2019, pp. 1069-1089.
Tin Tin Htar M, van Den Biggelaar AHJ, Sings H, et al. The impact of routine childhood immunization with higher-valent pneumococcal conjugate vaccines on antimicrobial-resistant pneumococcal diseases and carriage: a systematic literature review. Expert Rev Vaccines. 2019;18(10):1069-1089.
Tin Tin Htar, M., van Den Biggelaar, A. H. J., Sings, H., Ferreira, G., Moffatt, M., Hall-Murray, C., Verstraeten, T., Gessner, B. D., Schmitt, H. J., & Jodar, L. (2019). The impact of routine childhood immunization with higher-valent pneumococcal conjugate vaccines on antimicrobial-resistant pneumococcal diseases and carriage: a systematic literature review. Expert Review of Vaccines, 18(10), 1069-1089. https://doi.org/10.1080/14760584.2019.1676155
Tin Tin Htar M, et al. The Impact of Routine Childhood Immunization With Higher-valent Pneumococcal Conjugate Vaccines On Antimicrobial-resistant Pneumococcal Diseases and Carriage: a Systematic Literature Review. Expert Rev Vaccines. 2019;18(10):1069-1089. PubMed PMID: 31585049.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The impact of routine childhood immunization with higher-valent pneumococcal conjugate vaccines on antimicrobial-resistant pneumococcal diseases and carriage: a systematic literature review. AU - Tin Tin Htar,Myint, AU - van Den Biggelaar,Anita H J, AU - Sings,Heather, AU - Ferreira,Germano, AU - Moffatt,Margaret, AU - Hall-Murray,Cassandra, AU - Verstraeten,Thomas, AU - Gessner,Bradford D, AU - Schmitt,Heinz-Josef, AU - Jodar,Luis, Y1 - 2019/10/22/ PY - 2019/10/5/pubmed PY - 2020/7/14/medline PY - 2019/10/5/entrez KW - Antimicrobial resistance KW - PCV KW - Streptococcus pneumoniae KW - carriage KW - invasive pneumococcal disease KW - otitis media KW - pneumococcal KW - pneumococcal conjugate vaccine SP - 1069 EP - 1089 JF - Expert review of vaccines JO - Expert Rev Vaccines VL - 18 IS - 10 N2 - Introduction: The introduction of 7-valent pneumococcal conjugate vaccine (PCV7) in childhood immunization programs reduced antimicrobial-resistant pneumococcal infections by vaccine serotypes. However, emerging antimicrobial-resistant non-vaccine serotypes, particularly serotype 19A, attenuated the overall effect. In 2010, higher-valent PCVs became available containing serotypes that are prone to become antimicrobial-resistant, like serotype 7F in PCV10 and PCV13, and serotype 19A in PCV13.Areas covered: This review evaluated literature published between June 1, 2008 and June 1, 2017 reporting on the effect of PCV10 or PCV13 implementation in routine infant immunization schedules on antimicrobial-resistant invasive pneumococcal disease (IPD), otitis media (OM), and nasopharyngeal carriage (NPC) in children and adults.Expert opinion: In countries with relatively high prior pneumococcal antimicrobial resistance (AMR), PCV13 childhood vaccination programs have reduced antimicrobial-resistant IPD, OM, and NPC in children and IPD in adults. The effectiveness of PCV13 against serotype 19A is likely an important contributing factor. Only few studies have documented the impact of PCV10 on AMR. Multiple factors may influence observed decreases in pneumococcal AMR including antimicrobial stewardship, case definition, time since PCV10/13 introduction, and pre-PCV10/13 AMR levels. This review emphasizes the importance of including impact on AMR when evaluating the full public health of pneumococcal vaccination programs. SN - 1744-8395 UR - https://www.unboundmedicine.com/medline/citation/31585049/The_impact_of_routine_childhood_immunization_with_higher_valent_pneumococcal_conjugate_vaccines_on_antimicrobial_resistant_pneumococcal_diseases_and_carriage:_a_systematic_literature_review_ L2 - https://www.tandfonline.com/doi/full/10.1080/14760584.2019.1676155 DB - PRIME DP - Unbound Medicine ER -